Type of the Paper (Original article, Review, Communication, etc.)

**Title** (Should reflect manuscript content without creating false expectations. Should not include abbreviations)

Running title [max 40 characters]

Firstname Middle Initial Lastname 1, Firstname Middle Initial Lastname2 and Firstname Middle Initial Lastname 3

1Affiliation Author 1; e-mail author 1; ORCID number author 1 (register at: <https://orcid.org/>)

2Affiliation Author 2; e-mail author 2; ORCID number author 2 (register at: <https://orcid.org/>)

3Affiliation Author 3; e-mail author 3; ORCID number author 3 (register at: <https://orcid.org/>)

…

**\*** Corresponding author: e-mail@e-mail.com; Tel.: (optional; include country code; if there are multiple corresponding authors, add author initials) +xx-xxxx-xxx-xxxx (F.L.)

Received: date; Accepted: date; Published: date

**Abstract:** A structured paragraph of about 250 words maximum. For research articles, abstracts should give a pertinent overview of the work. Please, use the following style of structured abstracts: Objective(s), Methods, Results and Conclusions.

**Keywords:** keyword 1; keyword 2; keyword 3 (List five to seven pertinent keywords specific to the article; yet reasonably common within the subject discipline. Please, use [MeSH](https://urldefense.proofpoint.com/v2/url?u=http-3A__www.nlm.nih.gov_mesh_&d=DwMGaQ&c=lhMMI368wojMYNABHh1gQQ&r=wQICw5eT_zJ2LvSZBDMzxA&m=CIrNayYEPTzgKoe3hosSrMR42v_6TvQeQz7E8RywJKQ&s=XXCyCjh5iJ3DyyWKF1_GmjnLl_2KAs7sX_kVEiGLNsU&e=) terms)

0. How to Use This Template

The template details the sections that can be used in a manuscript. Note that each section has a corresponding style, which can be found in the ‘Styles’ menu of Word. Sections that are not mandatory are listed as such. The section titles given are for Articles. Review papers and other article types have a more flexible structure.

Remove this paragraph and start section numbering with 1. For any questions, please contact the editorial office of the journal.

1. Introduction

The introduction should briefly place the study in a broad context and highlight why it is important. It should define the purpose of the work and its significance. The current state of the research field should be reviewed carefully, and key publications cited. Please highlight controversial and diverging hypotheses when necessary. Finally, briefly mention the main aim of the work and highlight the principal conclusions. As far as possible, please keep the introduction comprehensible to scientists outside your field of research. References should be numbered in order of appearance and indicated by a numeral or numerals in square brackets, e.g., [1] or [2,3], or [4–6]. See the end of the document for further details on references.

2. Materials and Methods

Materials and Methods should be described with enough details to allow others to replicate and build on published results. Consider to include the following information.

**Design and population:** Type and design of the study; how and where it was carried out.

**Participant selection** (universe and/or samples, selection criteria, number of participants in each studied group)

**Study variables** (with their definitions)

**Procedures** (data collection and processing):

Methods used for assessments and when they were carried out Equipment and reagents (name, brand, country) Any modifications of a previously published method. Software programs used.

**Analysis**: Describe statistical methods in sufficient detail to allow verification of results Provide indicators of measurement error or uncertainty (e.g., SD, SEM, confidence intervals) Avoid exclusive reliance on p values, which do not provide information about effect magnitude.  Clinical trials should be registered; the public registry number will be reported. For information regarding reporting guidelines, authors should consult the EQUATOR Network web site (http://www.equator-network.org), which maintains a useful, up-to-date list of guidelines as they are published, with links to articles and checklists.

**AJNCD** adopts the definition of clinical trial accepted by the International Committee of Medical Journal Editors: a clinical trial is any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related. intervention and a health outcome. Health- related interventions are those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, behavioral treatments, and process-of-care changes.

Please note that publication of your manuscript implicates that you must make all materials, data, computer code, and protocols associated with the publication available to readers. Please disclose at the submission stage any restrictions on the availability of materials or information. New methods and protocols should be described in detail while well-established methods can be briefly described and appropriately cited.

Research manuscripts reporting large datasets that are deposited in a publicly available database should specify where the data have been deposited and provide the relevant accession numbers. If the accession numbers have not yet been obtained at the time of submission, please state that they will be provided during review. They must be provided prior to publication.

**Ethics:** Intervention studies involving humans, and other studies require ethical approval must list the authority that provided approval and the corresponding ethical approval code. Declare approval by institutional ethics committee(s). Studies that involve human subjects should follow the principles of the Helsinki Declaration.

Written informed consent must be obtained from participants or their legal representatives. It is the author’s responsibility to keep approval documents from ethics committee(s) and written informed consent (**AJNCD** may keep the right to request them). Authors who are members of business enterprises or financed by them should follow Good Publication Practice guidelines.

3. Results

This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation as well as the experimental conclusions that can be drawn.

Figures and Table

All figures and tables should be cited in the main text as Figure 1, Table 1, etc.

|  |  |
| --- | --- |
|  |  |

**Figure 1.** Figures should be placed in the main text near to the first time they are cited. A caption on a single line should be centered.

**Table 1.** This is a table. Tables should be placed in the main text near to the first time they are cited.

|  |  |  |
| --- | --- | --- |
| **Title 1** | **Title 2** | **Title 3** |
| entry 1 | data | data |
| entry 2 | data | data 1 |

1 Tables may have a footnote

4. Discussion

Authors should discuss the results and how they can be interpreted in perspective of previous studies and of the working hypotheses. The findings and their implications should be discussed in the broadest context possible. Future research directions may also be highlighted. The last paragraph of the discussion section should be a conclusion where you outline how the results can be used for public health, health policy, and for instance NCD surveillance and monitoring. Also, make sure to provide ideas for future research

**Author Contributions:** For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used “Conceptualization, X.X. and Y.Y.; methodology, X.X.; software, X.X.; validation, X.X., Y.Y. and Z.Z.; formal analysis, X.X.; investigation, X.X.; resources, X.X.; data curation, X.X.; writing—original draft preparation, X.X.; writing—review and editing, X.X.; visualization, X.X.; supervision, X.X.; project administration, X.X.; funding acquisition, Y.Y. All authors have read and agreed to the published version of the manuscript.” Authorship must be limited to those who have contributed substantially to the work reported.

**Funding:** Please add: “This research received no external funding” or “This research was funded by NAME OF FUNDER, grant number XXX” and “The APC was funded by XXX”. Check carefully that the details given are accurate and use the standard spelling of funding agency names at https://search.crossref.org/funding, any errors may affect your future funding.

**Acknowledgments:** In this section you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

**Conflicts of Interest:** Declare conflicts of interest or state “The authors declare no conflict of interest.” Authors must identify and declare any personal circumstances or interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. Any role of the funders in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results must be declared in this section. If there is no role, please state “The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results”.

**Data Availability Statement:** Data Availability Statements provide details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or generated during the study.

References

References must be numbered in order of appearance in the text (including citations in tables and legends) and listed individually at the end of the manuscript. We recommend preparing the references with a bibliography software package, such as EndNote, ReferenceManager or Zotero to avoid typing mistakes and duplicated references. Include the digital object identifier (DOI) for all references where available.

Citations and References in Supplementary files are permitted if they also appear in the reference list here.

In the text, reference numbers should be placed in square brackets [ ], and placed before the punctuation; for example [1], [1–3] or [1,3].

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list but may be mentioned in the text. If these references are included in the reference list, they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

When listing references, follow [AMA style](https://www.amamanualofstyle.com/view/10.1093/jama/9780190246556.001.0001/med-9780190246556-chapter-3-div1-46) and abbreviate names of journals according to the journal’s list in [PubMed](http://www.ncbi.nlm.nih.gov/pubmed). List all authors and/or editors up to 6; if more than 6, list the first 3 followed by "et al." Note: Journal references should include the issue number in parentheses after the volume number.

In order to generate and verify all doi’s of your references, please, go to [Simple Text Query](https://doi.crossref.org/simpleTextQuery), copy paste the entire list of references and get the doi’s added automatically to your reference list.

Examples of reference style:

1. Barengo NC, Diaz PA, Tuomilehto JO, Pratt M, Mouse M. Disease surveillance in Disneyland. AJNCD. 2019;11(7):152-158.  doi:10.0000000/000000000000
2. Murray CJL. Maximizing antiretroviral therapy in developing countries: the dual challenge of efficiency and quality [published online December 1, 2014]. JAMA. doi:10.1001/jama.2014.16376
3. Centers for Medicare & Medicaid Services. CMS proposals to implement certain disclosure provisions of the Affordable Care Act. http://www.cms.gov/apps/media/press/factsheet.asp?Counter=4221. Accessed January 30, 2012.
4. McPhee SJ, Winker MA, Rabow MW, Pantilat SZ, Markowitz AJ, eds. Care at the Close of Life: Evidence and Experience. New York, NY: McGraw Hill Medical; 2011.

For more examples of electronic references, click [here](https://www.amamanualofstyle.com/view/10.1093/jama/9780190246556.001.0001/med-9780190246556-chapter-3-div1-46).

**Publisher’s Note:** FIU stays neutral regarding jurisdictional claims in published maps and institutional affiliations.

|  |  |
| --- | --- |
| copyRight | © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |